-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $26

Benzinga·01/20/2026 15:46:52
Listen to the news
Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target from $29 to $26.